Abstract

It was professor Nana Svartz -1890-1986, Karolinska Institute, Stockholm, convinced that Rheumatic arthritis was caused by Streptococci. He later Hypothesised that combination with salicylic acid would deliver Sulfapyridine to affected joints. But it was only until late November 1940, when a 17yr old boy. With chronic Arthritis and colitis for 5yr was treated with Sulfapyridine in hospital for 9 months and later followed by sulphasalazine. His Colitis responded rapidly and he improved within a few months and later discharged. It was the then realised that colitis patients responded better than Rheumatic arthritis. This lead to the usage of sulfa drugs in patients with colitis and arthritis during that time. Mesalamine, it was discovered as the active anti-inflammatory moiety of sulfasalazine, which has been used to treat ulcerative colitis since the late 1940s. Sulfasalazine contains mesalamine or 5 ASA bound to sulfapyridine via an azo bond. It is released by bacterial enzyme azo reductase present in the small bowel and colon. Sulfapyridine is inactive, but is absorbed in the colon and is mostly responsible for hypersensitivity reactions and adverse effects associated with sulfasalazine. It is then excreted in the urine as free 5-ASA and N-Ac-5-ASA. Most of the side effects of salazopyrine drugs were attributed due to Sulfapyridine. Mesalamine compared were absorbed rapidly from gut and pre-systemically acetylated.

References

Citation

Citation: Sajith Sebsatian. “Development of Sulphasalazine a Follow through". Acta Scientific Gastrointestinal Disorders 4.11 (2021): 72-83.

Copyright

Copyright: © 2021 Sajith Sebsatian. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.